Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly

Phase 1/2 interim results have shown insufficient immune response in older adults, likely due to insufficient antigen concentration. A Phase 2b study with an improved antigen formulation, including proposed comparison with an authorised Covid-19 vaccine, is planned for Feb 2021.

GlaxoSmithKline